{
    "clinical_study": {
        "@rank": "50400", 
        "acronym": "LIPT", 
        "arm_group": [
            {
                "arm_group_label": "Active", 
                "arm_group_type": "Active Comparator", 
                "description": "Liraglutide s.c. 1,8mg daily for 26 weeks"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo s.c. 1,8mg daily for 26 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "Polycystic ovary syndrome (PCOS) affects 5-10% of women in fertile age. PCOS is associated\n      with metabolic syndrom, diabetes and and increased risk og cardiovascular disease.\n\n      The study investigates the effect af intervention with GLP-1-analog on risk markers of\n      cardiovascular disease in women with PCOS.\n\n      70 women will be included in af RCT.\n\n      Hypothesis: GLP-1-analog treatment in women with PCOS (without diabetes) will result in a\n      beneficial reduction in risk markers of vascular thrombosis and early cardiovascular\n      disease."
        }, 
        "brief_title": "LIPT - Liraglutide in Polycystic Ovary Syndrome", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Polycystic Ovary Syndrome", 
            "Cardiovascular Disease", 
            "Glucagon-Like Peptide 1"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Cardiovascular Diseases", 
                "Polycystic Ovary Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  PCOS\n\n          -  >18 years\n\n          -  premenopausal\n\n          -  BMI >25 og 25 and thereunder + insulin resistent\n\n        Exclusion Criteria (including):\n\n          -  actualt or intended pregnancy\n\n          -  inadeqvat contraception\n\n          -  hormonal contraception within 6 weeks\n\n          -  metfoomin, GLP-1-analog or DPP IV inhibitor within 3 months\n\n          -  medications affectiv hemostatic mechanisme\n\n          -  diabetes or other severe comorbidity\n\n          -  familar MEN\n\n          -  ..."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 25, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02073929", 
            "org_study_id": "EudraCT nr 2013-003862-15"
        }, 
        "intervention": {
            "arm_group_label": "Active", 
            "intervention_name": "Liraglutide", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 25, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Jens Faber, DSc", 
                    "phone": "+4538689016"
                }, 
                "facility": {
                    "address": {
                        "city": "Herlev", 
                        "country": "Denmark", 
                        "zip": "DK-2730"
                    }, 
                    "name": "Dept. of Medicine and Dept. of Obstetrics and Gynaecology, Herlev Hospital"
                }, 
                "investigator": {
                    "last_name": "Sven O Skouby, DSc", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "jens.faber@regionh.dk", 
                    "last_name": "Jens Faber, DSc", 
                    "phone": "+4538680916"
                }, 
                "contact_backup": {
                    "last_name": "Sven O Skouby, DSc", 
                    "phone": "+4538682933"
                }, 
                "facility": {
                    "address": {
                        "city": "Herlev", 
                        "country": "Denmark", 
                        "zip": "2730"
                    }, 
                    "name": "Dept. of Medicine and Dept. of Gyn-Obs, Herlev Hospital"
                }, 
                "investigator": {
                    "last_name": "Jens Faber, DSc", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "jens.faber@regionh.dk", 
                    "last_name": "Jens ber, professor", 
                    "phone": "4523235134"
                }, 
                "facility": {
                    "address": {
                        "city": "Herlev", 
                        "country": "Denmark", 
                        "zip": "2730"
                    }, 
                    "name": "Herlev Hospital, Dept of Gynecology"
                }, 
                "investigator": {
                    "last_name": "Jens Faber, professor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised, Double-blind, Placebo-controlled Study of the Effect of Liraglutide in Polycystic Ovary Syndrome on Risk Markers of Vascular Thrombosis.", 
        "other_outcome": {
            "measure": "Change in plasma level of Brain Natriuretic Peptide (BNP)", 
            "safety_issue": "No", 
            "time_frame": "At baseline and 26 weeks"
        }, 
        "overall_contact": {
            "email": "jens.faber@regionh.dk", 
            "last_name": "Jens O Faber, DSc", 
            "phone": "+4538689016"
        }, 
        "overall_contact_backup": {
            "email": "sven.olaf.skouby@regionh.dk", 
            "last_name": "Sven O Skouby, DSc", 
            "phone": "+4538682933"
        }, 
        "overall_official": {
            "affiliation": "Dept. of Medicine, Herlev Hospital", 
            "last_name": "Jens Faber, DSc", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Denmark: Danish Dataprotection Agency", 
                "Denmark: Danish Health and Medicines Authority", 
                "Denmark: Ethics Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Area under curve in a Thrombin Generation Test (TGT).", 
            "measure": "Change in Endogenous thrombin potential (ETP)", 
            "safety_issue": "No", 
            "time_frame": "At baseline and 26 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02073929"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Herlev Hospital", 
            "investigator_full_name": "Jens Faber", 
            "investigator_title": "Professor, DSc, Senior Hospital Physician", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Change in plasma level of Plasminogen activator inhibitor -1 PAI-1", 
            "safety_issue": "No", 
            "time_frame": "At baseline and 26 weeks"
        }, 
        "source": "Herlev Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jens Faber", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}